Clinical trials: Advanced Liver Cancers
Hepatocellular Carcinoma
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
Patients with advanced HCC, refractory to atezolizumab and bevacizumab /IO-based therapy will be treated with pembrolizumab and lenvatinib.
- Trial name
- NCT05101629
- Testing
- Pembrolizumab, Lenvatinib Capsules
- Where
- 12 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
To evaluate the safety and effectiveness of cell therapy using precision cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of…
- Conditions
- Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization, Advanced Liver Cancer
- Trial name
- NCT02873442
- Testing
- TACE, Precision Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ningbo Cancer Hospital
Hepatocellular Carcinoma (HCC)
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.
- Trial name
- NCT06487559
- Testing
- Livmoniplimab, Budigalimab
- Where
- 11 sites in China
- Volunteers
- 3 people
- Sponsor
- AbbVie
Carcinoma, Hepatocellular
A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.
The purpose of this study is to investigate the efficacy of GV1001 in locally advanced or metastatic HCC. Also the safety of GV1001 and immunogenicity will be evaluated.
- Trial name
- NCT00444782
- Testing
- GV1001
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 41 people
- Sponsor
- Pharmexa A/S
Hepatocellular Carcinoma
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
This is a prospective open label clinical trial in patients with advanced or metastatic liver cancer to assess the clinical and biological activity of RAD001 (Everolimus) in conjunction with Bevazicumab (Avastin).
- Trial name
- NCT00775073
- Testing
- Everolimus, Bevacizumab
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Gerhard Treiber
Advanced Liver Cancer
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced liver cancer.
- Trial name
- NCT03484962
- Testing
- Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer, cryotherapy
- Where
- 2 sites in China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Liver Neoplasms
Anlotinib for Hepatocellular Carcinoma
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment…
- Trial name
- AFHC (NCT04954521)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
Advanced Liver Cancers
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available…
- Trial name
- MORPHEUS-LIVER (NCT04524871)
- Testing
- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab
- Where
- 32 sites in United States, China and 5 more
- Volunteers
- 518 people
- Sponsor
- Hoffmann-La Roche
Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.
- Trial name
- NCT05406206
- Testing
- Fruquintinib, Hepatic Arterial Infusion Chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Peking University Cancer Hospital & Institute
Liver Cancer
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in China. Among them, only 10% patients can be diagnosed in early stage.
- Trial name
- NCT01932385
- Testing
- Sorafenib, Best Supportive Care
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Qingdao Central Hospital
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Advanced Solid Tumor, Hepatocellular Carcinoma
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.
- Trial name
- NCT06005740
- Testing
- TORL-4-500
- Where
- 10 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Hepatocellular Carcinoma
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.
- Trial name
- NCT05954897
- Testing
- Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Guangdong Provincial People's Hospital
Liver Cancer
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00128596
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pittsburgh
Carcinoma, Hepatocellular
A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma
Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year.
- Trial name
- THBC002 (NCT00440934)
- Testing
- Amplitude-modulated electromagnetic fields
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pasche, Boris, M.D.
Hepatocellular Carcinoma
DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
The main objective is to evaluate the value of dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) in prediction of response of patients with hepatocellular carcinoma (HCC) to treatment with Sorafenib assessed by…
- Trial name
- DCE-MRI (NCT01806740)
- Testing
- Gadoterate meglumine
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Guerbet
Hepatocellular Carcinoma
LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is determine whether the combination therapy with LEE011 and chemoembolization in patients with locally advanced Hepatocellular Carcinoma not amenable to curative therapies will provide greater efficacy…
- Trial name
- LEE001 (NCT02524119)
- Testing
- LEE011, Chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center